Drug Trial Radar · NCT05496335
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Aug 30, 2022
Primary completion
May 30, 2023
Study completion May 30, 2023
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective sequential administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) is in adult participants with moderate to severe GL. AGN-151586 is an investigational product being developed for the treatment of GL. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. One group will receive AGN-151586 followed by BOTOX and the other group will receive placebo followed by BOTOX. There is a 1 in 2 chance that participants will be assigned to placebo. Around 80 adult participants with moderate to severe GL will be enrolled in the study in approximately 10 sites around the United States. Participants will receive either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Eligible participants may then receive BOTOX injections on Day 30 and will be followed for up to 4 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Conditions
- Glabellar Lines
Interventions
AGN-151586Drug
Intramuscular Injection
BOTOXDrug
Intramuscular Injection
PlaceboDrug
Intramuscular Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants achieving "none" or "mild" on the Facial Wrinkle Scale (FWS) according to the investigator assessment of Glabellar Lines (GL) severity at maximum frownTime frame: At Day 60
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
The Eye Research Foundation /ID# 244430
Newport Beach, California
Cosmetic Laser Dermatology /ID# 244425
San Diego, California
AboutSkin Research, LLC /ID# 244416
Greenwood Village, Colorado
Skin Research Institute LLC /ID# 244424
Coral Gables, Florida
Skin and Cancer Associates, LLP /ID# 244415
Miami, Florida
DeNova Research /ID# 244421
Chicago, Illinois
Advanced Dermatology /ID# 244427
Lincolnshire, Illinois
Laser and Skin Surgery Center of Indiana /ID# 244423
Indianapolis, Indiana
Bellaire Dermatology Associates /ID# 244428
Bellaire, Texas
Premier Clinical Research /ID# 244429
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.